FDA Said to Approve Expanded Indication for Janssen's (JNJ) Zytiga
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) Janssen Bioscience is said to have gotten an expanded indicating for its late-stage prostate cancer drug, Zytiga. Headlines come from Bloomberg this afternoon.
Johnson & Johnson shares are positive on the session Monday.
Johnson & Johnson shares are positive on the session Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Capital Upgrades Johnson & Johnson (JNJ) to Buy
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- Nuvation Bio expands safusidenib trials after Phase 2 data update
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
